Physician profile
Scott Morgan Belliston
NPI 1235423393
$9,047.65
in general payments reported to CMS, 2019-2025
29 companies · $6,716 in 2025
The $6,716 reported for 2025 was more than what 87% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.52 · 2020: $32.94 · 2021: $442 · 2022: $434 · 2023: $768 · 2024: $627 · 2025: $6,716.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,420 · Food and Beverage: $2,691.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,420.00 |
| Food and Beverage | $2,690.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $3,107.03 | 2024-2025 | Zilbrysq, Briviact, Rystiggo |
| Genentech USA, INC. | $2,634.84 | 2021-2025 | Ocrevus |
| Novartis Pharmaceuticals Corporation | $860.31 | 2020-2025 | |
| Tg Therapeutics, INC. | $342.64 | 2023-2025 | |
| Horizon Therapeutics Plc | $327.59 | 2021-2023 | Uplizna |
| Genzyme Corporation | $291.13 | 2021-2025 | |
| Amgen INC. | $286.24 | 2024-2025 | Uplizna, Aimovig |
| Celgene Corporation | $266.14 | 2021-2024 | Zeposia |
| Emd Serono, INC. | $226.76 | 2021-2024 | Mavenclad, Mavenclad |
| Biogen, INC. | $144.27 | 2021-2025 | Spinraza, Tysabri, Vumerity |
| Abbvie INC. | $76.74 | 2021-2025 | Botox |
| Alexion Pharmaceuticals, INC. | $61.21 | 2022-2025 | Ultomiris |
| Argenx US, INC. | $53.22 | 2022-2025 | Vyvgart Hytrulo |
| Greenwich Biosciences, INC. | $48.97 | 2021 | |
| Lundbeck LLC | $48.10 | 2024-2025 | Vyepti |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Averitas Pharma INC. | $30.84 | 2025 | Qutenza |
| Ge Healthcare | $28.52 | 2019 | |
| Merz Pharmaceuticals, LLC | $23.89 | 2025 | Ampyra, Inbrija, Xeomin |
| Janssen Scientific Affairs, LLC | $23.84 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.65 | 2025 | Hyqvia |
| Eisai INC. | $22.13 | 2025 | |
| Invivyd INC | $17.83 | 2025 | Pemgarda |
| Springworks Therapeutics, INC. | $15.55 | 2025 | Gomekli |
| Pfizer INC. | $15.47 | 2024 | |
| Boston Scientific Corporation | $15.20 | 2021 | |
| Neurocrine Biosciences, INC. | $14.94 | 2025 | |
| Sanofi-Aventis U.S. LLC | $14.78 | 2021 | |
| Mallinckrodt Hospital Products INC. | $14.53 | 2025 | Acthar |
| Akcea Therapeutics, INC. | $11.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Belliston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.